Invention:
This invention uses innovative selective T-type antagonists in order to ease pain involved with chemotherapy-induced peripheral neuropathy (CIPN).
Background:
Chemotherapy remains a frontline treatment for many forms of cancer, however, chemotherapy agents commonly cause severe side effects such as CIPN. While opioids have been used to manage CIPN, the side effects of opioid use are often more overbearing than their benefits. CIPN is found in 64% of cancer patients from the beginning to the end phase of the cancer cycle and no effective treatments currently exist for CIPN-specific pain. This invention utilizes calcium antagonists to create a novel pain relief method for cancer patients experience CIPN.
Applications:
- Chronic pain market
- Cancer treatments
Advantages:
- Mediate analgesic effects
- Non-opioid based alternative
- Targets T-type Ca channels for pain management
